Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by Peregrine Capital Management LLC

Peregrine Capital Management LLC boosted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 18.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 880,517 shares of the biopharmaceutical company's stock after purchasing an additional 135,716 shares during the period. Peregrine Capital Management LLC owned approximately 0.29% of Amicus Therapeutics worth $8,294,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of FOLD. Sanctuary Advisors LLC purchased a new stake in Amicus Therapeutics in the second quarter valued at $138,000. Creative Planning raised its holdings in Amicus Therapeutics by 79.6% in the 3rd quarter. Creative Planning now owns 52,855 shares of the biopharmaceutical company's stock valued at $564,000 after buying an additional 23,433 shares during the period. Blue Trust Inc. lifted its position in Amicus Therapeutics by 1,705.4% in the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 2,831 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in Amicus Therapeutics by 141.1% in the third quarter. Assenagon Asset Management S.A. now owns 2,037,896 shares of the biopharmaceutical company's stock valued at $21,765,000 after buying an additional 1,192,489 shares during the last quarter. Finally, Legacy Capital Group California Inc. purchased a new position in Amicus Therapeutics during the third quarter worth about $206,000.

Analyst Ratings Changes

FOLD has been the topic of several recent analyst reports. Wells Fargo & Company decreased their price objective on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday. Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday. Morgan Stanley restated an "equal weight" rating and set a $12.00 price target (down from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. StockNews.com downgraded Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday. Finally, JPMorgan Chase & Co. raised their target price on Amicus Therapeutics from $16.00 to $17.00 and gave the company an "overweight" rating in a report on Tuesday, November 12th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $16.75.

Insiders Place Their Bets

In related news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total value of $75,150.00. Following the transaction, the chief executive officer now owns 886,654 shares of the company's stock, valued at $8,884,273.08. This represents a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 2.20% of the stock is currently owned by company insiders.

Amicus Therapeutics Stock Up 1.3 %

FOLD stock traded up $0.12 during mid-day trading on Friday, reaching $9.19. The company had a trading volume of 2,603,411 shares, compared to its average volume of 2,128,267. The firm has a fifty day simple moving average of $9.56 and a 200 day simple moving average of $10.41. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. The company has a market capitalization of $2.82 billion, a price-to-earnings ratio of -51.06, a price-to-earnings-growth ratio of 1.51 and a beta of 0.61. Amicus Therapeutics, Inc. has a fifty-two week low of $8.78 and a fifty-two week high of $14.02.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.